Targeting a specific receptor to prevent and treat cancer
Unique targeting of PPARβ/δ regulation for cancer prevention and therapy
This study is looking at a new way to help treat colorectal cancer by using special compounds that target a specific receptor in the body, which could make current treatments work better and help overcome challenges like drug resistance, ultimately aiming to offer more effective options for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pennsylvania State University, the NIH-funded |
| Lab location | 1 site (University Park, United States) |
| Project ID | NIH-10747931 on NIH RePORTER |
What this research studies
This research investigates the use of selective repressive ligands that target the PPARβ/δ receptor to inhibit and treat colorectal cancer. By focusing on these specific ligands, the study aims to enhance the effectiveness of existing cancer therapies and overcome drug resistance. The approach involves understanding how these ligands can selectively repress gene expression related to cancer progression and metastasis, potentially leading to more precise treatment options for patients. The research is designed to explore new molecular mechanisms that could improve cancer therapy outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with colorectal cancer, especially those exhibiting resistance to existing treatments.
Not a fit: Patients with cancers other than colorectal cancer or those who do not have drug-resistant tumors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for colorectal cancer, particularly for patients who have not responded well to current therapies.
How similar studies have performed: Previous research has shown promise in targeting similar molecular pathways for cancer treatment, indicating that this approach could be a valuable addition to existing therapies.
Where this research is happening
University Park, United States
- Pennsylvania State University, the — University Park, United States (Active)
Researchers
- Principal investigator: Peters, Jeffrey M — Pennsylvania State University, the
- Study coordinator: Peters, Jeffrey M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.